Article
SETD1B mutations confer apoptosis resistance and BCL2 independence in B cell lymphoma.
The Journal of experimental medicine - 7 Oct 2024
Portelinha Ana, Wang Shenqiu, Parsa Sara, Jiang Man, Gorelick Alexander N, Mohanty Sagarajit, Sharma Soumya, de Stanchina Elisa, Berishaj Marjan, Zhao Chunying, Heward James, Aryal Neeraj K, Tavana Omid, Wen Jiayu, Fitzgibbon Jude, Dogan Ahmet, Younes Anas, Melnick Ari M, Wendel Hans-Guido
Abstract excerpt
The translocation t(14;18) activates BCL2 and is considered the initiating genetic lesion in most follicular lymphomas (FL). Surprisingly, FL patients fail to respond to the BCL2 inhibitor, Venetoclax. We show that mutations and deletions affecting the histone lysine methyltransferase SETD1B (KMT2G) occur in 7% of FLs and 16% of diffuse large B cell lymphomas (DLBCL). Deficiency in SETD1B confers striking...
Topics
- Animals
- Humans
- Mice
- Apoptosis
- Bridged Bicyclo Compounds, Heterocyclic
- Cell Line, Tumor
- DNA-Binding Proteins
- Drug Resistance, Neoplasm
- Histone-Lysine N-Methyltransferase